Dr Chantal Bader, postdoc in the Department of Microbial Natural Products at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), has been awarded a grant from the Hans-and-Ruth-Giessen-Foundation on 29...
The human recombinant anti-SARS-CoV-2 antibody COR-101 was developed in close cooperation of Technische Universität Braunschweig, the Helmholtz Centre for Infection Research (HZI) and the biotech company YUMAB GmbH in...
Welche Faktoren sind verantwortlich dafür, dass einige Menschen nach einer Infektion mit dem Coronavirus SARS-CoV-2 schwer erkranken, während andere nur leichte oder gar keine Symptome entwickeln? Dieser Frage gehen...
NFDI4Microbiota is set to become part of Germany’s national research data infrastructure (NFDI). In May 2021, a panel of experts recommended that the consortium should receive NFDI funding – and now the Joint Science...
The Helmholtz Centre for Infection Research (HZI) has appointed PD Dr Fabian Leendertz as founding director of the Helmholtz Institute for One Health (HIOH) in Greifswald on 26 May 2021. At the same time, he accepted...
How can we apply the knowledge we have gained so far to better overcome the current crisis and prevent another pandemic in future? Helmholtz aims to find answers to these questions with two new, interdisciplinary...
Am I infected with SARS-CoV-2? Is it one of the dangerous variants? Being able to answer these and more questions with a single efficient diagnostic test can be decisive for gauging the spread of disease and selecting...
On the occasion of World Tuberculosis Day, Jennifer Herrmann, scientist in the department Microbial Natural Products at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), talks about the epidemiology...
After exposure to a virus through infection or vaccination, the body activates a number of cells and mechanisms that can provide targeted defense against the pathogen. For the global containment of the SARS-CoV-2...
